LUNG
Pulmonx Corporation
NASDAQ · Healthcare · Medical - Devices · US
$2.21
−2.21%Year over year
Reported trailing growth
- Revenue
- -3.4%
- EBITDA
- +20.7%
- EBIT
- +18.6%
- EPS
- +19.6%
- Free cash flow
- +4.2%
- Operating cash flow
- +1.9%
Forward estimates
Based on analyst estimates
- Revenue
- +9.0%
- EBITDA
- +21.2%
- EPS
- +19.5%
Three-year CAGR
- Revenue
- +19.0%
- EBITDA
- +3.2%
- EBIT
- +7.0%
- Net income
- +4.2%
- EPS
- +7.6%
- Free cash flow
- +0.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026